Related Experiment Video

Updated: Aug 4, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

195

Lovastatin inhibits erythroleukemia progression through KLF2-mediated suppression of MAPK/ERK signaling

Jian Gao1,2, Jifen Hu1,2, Fang Yu1,2

  • 1State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, Guizhou, 550014, People's Republic of China.

BMC Cancer
|April 4, 2023
PubMed
Abstract

Insights

Lovastatin inhibits leukemia cell growth by inducing cell cycle arrest and apoptosis. This cholesterol-lowering drug suppresses MAPK signaling and activates tumor suppressor KLF2, offering a potential new cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Lovastatin, a cholesterol-lowering drug, shows anti-neoplastic effects in various cancers.
  • The precise mechanism of lovastatin's anti-leukemic action requires further elucidation.

Purpose of the Study:

  • To investigate the mechanism by which lovastatin inhibits leukemic cell growth.
  • To explore the role of KLF2, FAM83A, DDIT4, and MAPK signaling in lovastatin's anti-leukemic effects.

Main Methods:

  • RNA sequencing (RNAseq) to analyze gene expression changes in lovastatin-treated leukemic cells.
  • In vivo studies using a mouse model of erythroleukemia and in vitro assays (cell cycle, apoptosis, Western blotting, RT-qPCR) to assess lovastatin's effects.
  • Gene knockdown experiments using lentivirus-shRNA to evaluate the roles of FAM83A, DDIT4, and KLF2.

Main Results:

  • Lovastatin inhibited leukemia progression in vivo and induced G1 cell cycle arrest and apoptosis in vitro.
  • Lovastatin suppressed ERK1/2 phosphorylation by downregulating FAM83A and DDIT4, while inducing the tumor suppressor KLF2.
  • KLF2 knockdown reversed lovastatin's inhibitory effects, confirming its crucial role. KLF2 activation also induced cholesterol biosynthesis genes.

Conclusions:

  • Lovastatin inhibits leukemia cell growth via KLF2-mediated suppression of FAM83A/DDIT4/MAPK signaling.
  • Activation of cholesterol biosynthesis pathways by KLF2 may also contribute to lovastatin's anti-leukemic effects.
Keywords:
Cholesterol biosynthesisERK1/2FAM38AKLF2Leukemia progressionLovastatin

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
719
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.7K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.6K